ERBB2 and breast carcinoma: HRD prevalence varies across breast cancer subtypes, with TNBC exhibiting the highest rates (50–70%), followed by HER2-positive (30–40%), luminal A (15–25%), luminal B (20–35%), and HR+/HER2− (15–20%) [75].